Phagocytosis can be induced via the engagement of Fcγ receptors by antibody-opsonized
material. Furthermore, the efficiency of antibody-induced effector functions has been shown to …

The human phase 2B RV144 ALVAC-HIV vCP1521/AIDSVAX B/E vaccine trial, held in
Thailand, resulted in an estimated 31.2% efficacy against HIV infection. By contrast, vaccination …

While the induction of a neutralizing antibody response against HIV remains a daunting goal,
data from both natural infection and vaccine-induced immune responses suggest that it …

While antibody titers and neutralization are considered the gold standard for the selection of
successful vaccines, these parameters are often inadequate predictors of protective …

Preclinical studies of viral vector–based HIV-1 vaccine candidates have previously shown
partial protection against neutralization-resistant virus challenges in rhesus monkeys. In this …

Elite controllers (ECs) represent a unique model of a functional cure for HIV-1 infection as
these individuals develop HIV-specific immunity able to persistently suppress viremia. …

Heterologous prime-boost immunization strategies have the potential to augment COVID-19
vaccine efficacy. We longitudinally profiled severe acute respiratory syndrome coronavirus …

In vivo, the activity of antibodies relies critically on properties of both the variable domain,
responsible for antigen recognition, and the constant domain, responsible for innate immune …

A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)–HIV and
gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution of …

Antibodies are widely considered to be a frequent primary and often mechanistic correlate
of protection of approved vaccines; thus evaluating the antibody response is of critical …